Literature DB >> 8552899

A simulation study used to design the sequential monitoring plan for a clinical trial.

M M Brooks1, A Hallstrom, M Peckova.   

Abstract

In designing a sequential monitoring plan for the AVID (Antiarrhythmics Versus Implantable Defibrillators) study, a multi-centred clinical trial, we completed a simulation study to help ourselves and the Data Safety Monitoring Board understand the implications of various monitoring plans. In particular, we compared three test statistics and three use functions. Simulation was based on approximate trial parameters and two plausible but distinct alternative hypotheses. The power to detect a difference between the two treatment arms was computed as a function of time. The simulated results illuminate several of the important statistical and ethical issues involved in selecting a sequential monitoring plan and illustrate how one can use simulations to design a clinical trial.

Mesh:

Substances:

Year:  1995        PMID: 8552899     DOI: 10.1002/sim.4780142006

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Graphene-VP40 interactions and potential disruption of the Ebola virus matrix filaments.

Authors:  Jeevan B Gc; Rudramani Pokhrel; Nisha Bhattarai; Kristen A Johnson; Bernard S Gerstman; Robert V Stahelin; Prem P Chapagain
Journal:  Biochem Biophys Res Commun       Date:  2017-09-13       Impact factor: 3.575

2.  Novel and Structurally Diversified Bacterial DNA Gyrase Inhibitors Discovered through a Fluorescence-Based High-Throughput Screening Assay.

Authors:  Eddy E Alfonso; Zifang Deng; Daniel Boaretto; Becky L Hood; Stefan Vasile; Layton H Smith; Jeremy W Chambers; Prem Chapagain; Fenfei Leng
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-02

3.  A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine.

Authors:  Kathryn Del Vecchio; Cary T Frick; Jeevan B Gc; Shun-Ichiro Oda; Bernard S Gerstman; Erica Ollmann Saphire; Prem P Chapagain; Robert V Stahelin
Journal:  J Biol Chem       Date:  2018-01-18       Impact factor: 5.157

4.  Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.

Authors:  Shayna Sandhaus; Prem P Chapagain; Yuk-Ching Tse-Dinh
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

5.  Plasma membrane association facilitates conformational changes in the Marburg virus protein VP40 dimer.

Authors:  Nisha Bhattarai; Jeevan B Gc; Bernard S Gerstman; Robert V Stahelin; Prem P Chapagain
Journal:  RSC Adv       Date:  2017-04-26       Impact factor: 3.361

6.  Mutation of Hydrophobic Residues in the C-Terminal Domain of the Marburg Virus Matrix Protein VP40 Disrupts Trafficking to the Plasma Membrane.

Authors:  Kaveesha J Wijesinghe; Luke McVeigh; Monica L Husby; Nisha Bhattarai; Jia Ma; Bernard S Gerstman; Prem P Chapagain; Robert V Stahelin
Journal:  Viruses       Date:  2020-04-24       Impact factor: 5.048

7.  Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays.

Authors:  Linjia Su; Nadezda Bryan; Sabrina Battista; Juliano Freitas; Alyssa Garabedian; Federica D'Alessio; Miriam Romano; Fabiana Falanga; Alfredo Fusco; Lidia Kos; Jeremy Chambers; Francisco Fernandez-Lima; Prem P Chapagain; Stefan Vasile; Layton Smith; Fenfei Leng
Journal:  Sci Rep       Date:  2020-11-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.